The clinical development of antibody–drug conjugates — lessons from leukaemia

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations

Abstract

Advances in our understanding of cancer biology have enabled drug development to progress towards better targeted therapies that are both more effective and safer owing to their lack of off-target toxicities. In this regard, antibody–drug conjugates (ADCs), which have the potential to combine the selectivity of therapeutic antibodies with the cytotoxicity of highly toxic small molecules, are a rapidly developing drug class. The complex and unique structure of an ADC, composed of a monoclonal antibody conjugated to a potent cytotoxic payload via a chemical linker, is designed to selectively target a specific tumour antigen. The success of an ADC is highly dependent on the specific properties of its components, all of which have implications for the stability, cytotoxicity, pharmacokinetics and antitumour activity of the ADC. The development of therapeutic ADCs, including gemtuzumab ozogamicin and inotuzumab ozogamicin, provided great knowledge of the refinements needed for the optimization of such agents. In this Review, we describe the key components of ADC structure and function and focus on the clinical development and subsequent utilization of two leukaemia-directed ADCs — gemtuzumab ozogamicin and inotuzumab ozogamicin — as well as on the mechanisms of resistance and predictors of response to these two agents.

Original languageEnglish (US)
Pages (from-to)418-433
Number of pages16
JournalNature Reviews Clinical Oncology
Volume18
Issue number7
DOIs
StatePublished - Jul 2021

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'The clinical development of antibody–drug conjugates — lessons from leukaemia'. Together they form a unique fingerprint.

Cite this